Focus on mirtazapine: A new antidepressant with noradrenergic and specific serotonergic activity

Formulary

Volumn 31, Issue 6, 1996, Pages 455-469

  Kehoe, William A ^a   Schorr, Robert B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004463533     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995;4(Suppl 1):29-38.
2. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Results from a placebo-controlled trial. Drug Invest 1994;8:339-44.
3. Sorensen M, Jorgensen J, Viby-Mogensen J, et al. A double-blind group comparative study using the new antidepressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339-46.
4. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-25.
5. Halikas JA. Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10(Suppl):S125-S33.
6. de Montigny C, Haddjeri N, Mongeau R, Blier P. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995;4(Suppl 1):13-17.
7. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: Acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10 (Suppl 4):11-17.
8. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10(Suppl):S107-S18.
9. Peroutka S. Serotonin receptor subtypes. Their evolution and clinical relevance. CNS Drugs 1995;4(Suppl 1):18-28.
10. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10(Suppl):S83-S96.
11. Sitsen JMA, Zivkov M. Mirtazapine. Clinical profile. CNS Drugs 1995;4 (Suppl 1):39-48.
12. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady-state of mirtazapine from Remeron tablets. Hum Psychopharmacol 1995;10(Suppl):S97-S106.
13. Khan MC. A randomized, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995; 10(Suppl):S119-S24.
14. Claghom JL, Lesem MD. A double-blind placebo-controlled study or Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171.
15. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145-50.
16. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-6.
17. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: A 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
18. Kasper S. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10(Suppl 4):25-35.
19. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: A meta-analysis. Hum Psychopharmacol 1995;(Suppl): S135-S45.
20. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study or Org 3770. Hum Psychopharmacol 1995;10:263-71.
21. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: A double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9.
22. Montgomery SA. Safety of mirtazapine: A review. Int Clin Psychopharmacol 1995;10(Suppl 4):37-45.
23. Anon. Organon Remeron is first alpha-2 receptor antagonist antidepressant recommended by advisory committee: Labeling should note neutropenia risk. F-D-C Reports-"The Pink Sheet" October 23. 1995, pp.16-17.
24. Kuitunen T. Drug and ethanol effects on the clinical test for drunkenness: Single doses of ethanol, hypnotic drugs and antidepressant drugs. Pharmacol Toxicol 1994;75:91-8.
25. Mattila M, Mattila MJ, Vrijmoed-de Vries M, Kuitunen T. Actions and interactions of psychotropic drugs on human performance and mood: Single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 1989;65:81-8.
26. Murdoch DL, Ashgar J, Ankier SI, et al. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects. Proceedings of the BPS: 1992 Sept 9-11:76P.
27. van Praag HM, Asnis GM, Kahn RS, et al. Monoamines and abnormal behavior. A multi-aminergic perspective. Br J Psychiatry 1990;157:723-34.